Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hetrombopag - Jiangsu Hengrui Medicine Co.

Drug Profile

Hetrombopag - Jiangsu Hengrui Medicine Co.

Alternative Names: Hengqu; Herombopag olamine; Hetrombopag olamine; Hytrapopapa ethanolamine; Hytrapopapamin; SHR 8735; SHR 8735 olamine

Latest Information Update: 09 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Atridia; Jiangsu Hengrui Medicine Co.
  • Class Antianaemics; Antihaemorrhagics; Aza compounds; Carboxylic acids; Furans; Pyrazolones; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombocytopenia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aplastic anaemia; Idiopathic thrombocytopenic purpura
  • Phase III Thrombocytopenia
  • No development reported Unspecified

Most Recent Events

  • 09 Apr 2024 Jiangsu HengRui Medicine plans a phase I trial for Idiopathic thrombocytopenic purpura (In Volunteers) in China (PO, Tablet) in April 2024 (NCT06346925)
  • 28 Mar 2024 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in Australia (PO)
  • 02 Nov 2023 Jiangsu HengRui Medicine completes a phase I bioequivalence trial in Healthy volunteers in China (PO)(NCT05088655)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top